Lynda Marie Vrooman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 29 | 2024 | 1551 | 4.460 |
Why?
|
Asparaginase | 16 | 2024 | 240 | 2.700 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 382 | 0.910 |
Why?
|
Leukemic Infiltration | 1 | 2022 | 47 | 0.800 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 226 | 0.610 |
Why?
|
Child | 43 | 2024 | 80162 | 0.460 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13637 | 0.440 |
Why?
|
Drug Hypersensitivity | 4 | 2021 | 917 | 0.430 |
Why?
|
Razoxane | 2 | 2011 | 43 | 0.400 |
Why?
|
Osteonecrosis | 3 | 2022 | 229 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11740 | 0.360 |
Why?
|
Dexamethasone | 2 | 2020 | 1947 | 0.360 |
Why?
|
Erwinia | 1 | 2010 | 21 | 0.350 |
Why?
|
Child, Preschool | 23 | 2024 | 42254 | 0.340 |
Why?
|
Polyethylene Glycols | 5 | 2021 | 1188 | 0.330 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1896 | 0.330 |
Why?
|
Neoplasms | 7 | 2024 | 22164 | 0.320 |
Why?
|
Neoplasm, Residual | 3 | 2020 | 1008 | 0.290 |
Why?
|
Quality of Life | 7 | 2024 | 13361 | 0.280 |
Why?
|
Infant | 19 | 2024 | 36205 | 0.280 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5670 | 0.280 |
Why?
|
Survivors | 7 | 2024 | 2371 | 0.280 |
Why?
|
Graft vs Host Disease | 2 | 2017 | 3030 | 0.270 |
Why?
|
Adolescent | 30 | 2024 | 88313 | 0.260 |
Why?
|
Ikaros Transcription Factor | 2 | 2018 | 232 | 0.260 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1520 | 0.240 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1876 | 0.220 |
Why?
|
Leukemia | 2 | 2023 | 1522 | 0.220 |
Why?
|
Neoplasms, Second Primary | 4 | 2020 | 1051 | 0.210 |
Why?
|
Fatigue | 2 | 2023 | 1551 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9031 | 0.200 |
Why?
|
Escherichia coli | 5 | 2016 | 4218 | 0.200 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6814 | 0.190 |
Why?
|
Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2021 | 8 | 0.190 |
Why?
|
Cardiotonic Agents | 2 | 2016 | 539 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2022 | 173 | 0.170 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 168 | 0.160 |
Why?
|
Humans | 48 | 2024 | 761423 | 0.160 |
Why?
|
Methylprednisolone | 1 | 2020 | 384 | 0.160 |
Why?
|
Hodgkin Disease | 2 | 2021 | 1378 | 0.160 |
Why?
|
Doxorubicin | 4 | 2023 | 2224 | 0.150 |
Why?
|
Risk Assessment | 2 | 2018 | 23990 | 0.150 |
Why?
|
Young Adult | 18 | 2024 | 59207 | 0.150 |
Why?
|
Anemia, Aplastic | 1 | 2020 | 230 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2020 | 857 | 0.150 |
Why?
|
Survival Rate | 4 | 2021 | 12720 | 0.150 |
Why?
|
Thymidylate Synthase | 1 | 2016 | 74 | 0.140 |
Why?
|
Osteosarcoma | 1 | 2023 | 897 | 0.140 |
Why?
|
Follow-Up Studies | 8 | 2021 | 39117 | 0.140 |
Why?
|
Morbidity | 1 | 2022 | 1750 | 0.140 |
Why?
|
Executive Function | 2 | 2023 | 1389 | 0.130 |
Why?
|
Cytogenetics | 1 | 2016 | 198 | 0.130 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15498 | 0.130 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 305 | 0.130 |
Why?
|
Female | 25 | 2024 | 392581 | 0.120 |
Why?
|
Risk Factors | 9 | 2024 | 74167 | 0.120 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2011 | 3613 | 0.120 |
Why?
|
Prognosis | 5 | 2024 | 29620 | 0.120 |
Why?
|
Nutrition Surveys | 1 | 2022 | 1728 | 0.120 |
Why?
|
Mitochondria, Heart | 1 | 2016 | 229 | 0.120 |
Why?
|
Leukocyte Count | 1 | 2018 | 1596 | 0.120 |
Why?
|
Mood Disorders | 1 | 2020 | 1127 | 0.110 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2018 | 682 | 0.110 |
Why?
|
Lymphoma | 1 | 2023 | 1901 | 0.110 |
Why?
|
Male | 22 | 2024 | 360736 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1223 | 0.110 |
Why?
|
Age Factors | 4 | 2018 | 18400 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1703 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 897 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2021 | 1376 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 646 | 0.110 |
Why?
|
Fractures, Bone | 2 | 2016 | 2046 | 0.100 |
Why?
|
Hypersensitivity | 1 | 2021 | 1158 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12058 | 0.100 |
Why?
|
Adult | 14 | 2024 | 221148 | 0.100 |
Why?
|
Survival Analysis | 2 | 2018 | 10089 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1866 | 0.090 |
Why?
|
Family | 1 | 2022 | 3197 | 0.090 |
Why?
|
Bone Neoplasms | 1 | 2023 | 2529 | 0.090 |
Why?
|
DNA, Mitochondrial | 1 | 2016 | 865 | 0.090 |
Why?
|
Pancreatitis | 1 | 2017 | 1096 | 0.090 |
Why?
|
Methotrexate | 1 | 2016 | 1718 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1843 | 0.080 |
Why?
|
Escherichia coli Proteins | 1 | 2015 | 1067 | 0.080 |
Why?
|
Incidence | 5 | 2024 | 21341 | 0.080 |
Why?
|
Bone Density | 1 | 2021 | 3551 | 0.080 |
Why?
|
Pain | 1 | 2023 | 5071 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1600 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10194 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 2020 | 0.070 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2016 | 1081 | 0.070 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2023 | 678 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5335 | 0.060 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2009 | 651 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2507 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1780 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 10203 | 0.060 |
Why?
|
Pharmacogenetics | 1 | 2009 | 675 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2176 | 0.060 |
Why?
|
Chronic Disease | 2 | 2017 | 9320 | 0.060 |
Why?
|
Recurrence | 1 | 2016 | 8469 | 0.060 |
Why?
|
Transplantation, Homologous | 2 | 2024 | 4808 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 3051 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5840 | 0.050 |
Why?
|
Physicians | 1 | 2021 | 4591 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2016 | 3979 | 0.050 |
Why?
|
Chromosome Aberrations | 1 | 2009 | 1771 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4852 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5819 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2022 | 64651 | 0.050 |
Why?
|
Vitamin D Deficiency | 1 | 2010 | 1386 | 0.050 |
Why?
|
Immunotherapy | 1 | 2016 | 4650 | 0.050 |
Why?
|
Pons | 1 | 2021 | 240 | 0.040 |
Why?
|
Remission Induction | 2 | 2020 | 2395 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5665 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9612 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2021 | 467 | 0.040 |
Why?
|
Bone Diseases, Metabolic | 1 | 2021 | 409 | 0.040 |
Why?
|
Hematologic Diseases | 1 | 2021 | 496 | 0.040 |
Why?
|
Blindness | 1 | 2021 | 584 | 0.040 |
Why?
|
Vitamin D | 1 | 2010 | 3301 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2023 | 5246 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2021 | 1377 | 0.030 |
Why?
|
Health Status | 1 | 2010 | 4075 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2024 | 80582 | 0.030 |
Why?
|
Pilot Projects | 2 | 2023 | 8633 | 0.030 |
Why?
|
Memory, Short-Term | 1 | 2023 | 982 | 0.030 |
Why?
|
Middle Aged | 5 | 2024 | 220826 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 2016 | 213 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2011 | 26212 | 0.030 |
Why?
|
Injections, Spinal | 1 | 2016 | 318 | 0.030 |
Why?
|
Electron Transport Complex IV | 1 | 2016 | 190 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2021 | 809 | 0.030 |
Why?
|
United States | 2 | 2021 | 72339 | 0.030 |
Why?
|
Electron Transport Complex I | 1 | 2016 | 153 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 413 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2022 | 12456 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2015 | 554 | 0.030 |
Why?
|
Hearing Loss | 1 | 2021 | 783 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2009 | 5305 | 0.030 |
Why?
|
Time Factors | 2 | 2015 | 39975 | 0.030 |
Why?
|
Drug Substitution | 1 | 2016 | 290 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2413 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2161 | 0.030 |
Why?
|
Acute Disease | 1 | 2022 | 7238 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2120 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2023 | 7045 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2016 | 962 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2230 | 0.020 |
Why?
|
Sunlight | 1 | 2010 | 337 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3460 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3639 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 6086 | 0.020 |
Why?
|
Blood Glucose | 1 | 2021 | 6391 | 0.020 |
Why?
|
Insulin | 1 | 2021 | 6602 | 0.020 |
Why?
|
Memory | 1 | 2016 | 2187 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6532 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2016 | 1943 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3122 | 0.020 |
Why?
|
Attention | 1 | 2016 | 2395 | 0.020 |
Why?
|
Body Mass Index | 1 | 2023 | 12951 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6479 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2218 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8320 | 0.010 |
Why?
|
Parathyroid Hormone | 1 | 2010 | 1803 | 0.010 |
Why?
|
Prospective Studies | 2 | 2023 | 54415 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7584 | 0.010 |
Why?
|
Aged | 3 | 2023 | 169235 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3304 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9277 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13009 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10548 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12938 | 0.010 |
Why?
|
Attitude to Health | 1 | 2010 | 2025 | 0.010 |
Why?
|
Sleep | 1 | 2016 | 4766 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14599 | 0.010 |
Why?
|
Cognition | 1 | 2016 | 6986 | 0.010 |
Why?
|
Health Behavior | 1 | 2010 | 2641 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8529 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2010 | 3414 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15941 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17912 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26112 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 41446 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15717 | 0.010 |
Why?
|